Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies

Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-c...

Descripción completa

Detalles Bibliográficos
Autores: Sancho Saldaña, Agustín, Gil-Sánchez, Anna, Quirant Sánchez, Bibiana, Nogueras Penabad, Lara, Peralta Moncusí, Silvia, Solana Moga, M. José, González Mingot, Cristina, Gallego, Yhovany, Quibus, Laura, Ramo Tello, Cristina, Presas Rodríguez, Silvia, Martínez Cáceres, Eva, Torres Cabestany, Pascual, Hervás, J.V., Valls Marsal, Joan, Brieva Ruiz, Luis
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/84518
Acceso en línea:https://doi.org/10.3390/jcm11092509
http://hdl.handle.net/10459.1/84518
Access Level:acceso abierto
Palabra clave:Multiple sclerosis
COVID-19
SARS-CoV-2
DMT
Seroprevalence
id ES_328a46d9d1f49bccbd38bdf100e85b2a
oai_identifier_str oai:repositori.udl.cat:10459.1/84518
network_acronym_str ES
network_name_str España
repository_id_str
spelling Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying TherapiesSancho Saldaña, AgustínGil-Sánchez, AnnaQuirant Sánchez, BibianaNogueras Penabad, LaraPeralta Moncusí, SilviaSolana Moga, M. JoséGonzález Mingot, CristinaGallego, YhovanyQuibus, LauraRamo Tello, CristinaPresas Rodríguez, SilviaMartínez Cáceres, EvaTorres Cabestany, PascualHervás, J.V.Valls Marsal, Joan Brieva Ruiz, LuisMultiple sclerosisCOVID-19SARS-CoV-2DMTSeroprevalenceBackground: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26.4% vs. 10.7%, p = 0.006). Although patients taking interferon were significantly older (49.1 vs. 43.5, p = 0.003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2.99 (1.38; 6.36), p = 0.006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT.MDPI2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://doi.org/10.3390/jcm11092509http://hdl.handle.net/10459.1/84518reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésReproducció del document publicat a https://doi.org/10.3390/jcm11092509Journal of Clinical Medicine, 2022, vol. 11, núm. 9, art. 2509.cc-by (c) Agustín Sancho Saldaña et al., 2022info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/oai:repositori.udl.cat:10459.1/845182026-06-24T12:42:17Z
dc.title.none.fl_str_mv Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
spellingShingle Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
Sancho Saldaña, Agustín
Multiple sclerosis
COVID-19
SARS-CoV-2
DMT
Seroprevalence
title_short Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_full Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_fullStr Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_full_unstemmed Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
title_sort Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
dc.creator.none.fl_str_mv Sancho Saldaña, Agustín
Gil-Sánchez, Anna
Quirant Sánchez, Bibiana
Nogueras Penabad, Lara
Peralta Moncusí, Silvia
Solana Moga, M. José
González Mingot, Cristina
Gallego, Yhovany
Quibus, Laura
Ramo Tello, Cristina
Presas Rodríguez, Silvia
Martínez Cáceres, Eva
Torres Cabestany, Pascual
Hervás, J.V.
Valls Marsal, Joan
Brieva Ruiz, Luis
author Sancho Saldaña, Agustín
author_facet Sancho Saldaña, Agustín
Gil-Sánchez, Anna
Quirant Sánchez, Bibiana
Nogueras Penabad, Lara
Peralta Moncusí, Silvia
Solana Moga, M. José
González Mingot, Cristina
Gallego, Yhovany
Quibus, Laura
Ramo Tello, Cristina
Presas Rodríguez, Silvia
Martínez Cáceres, Eva
Torres Cabestany, Pascual
Hervás, J.V.
Valls Marsal, Joan
Brieva Ruiz, Luis
author_role author
author2 Gil-Sánchez, Anna
Quirant Sánchez, Bibiana
Nogueras Penabad, Lara
Peralta Moncusí, Silvia
Solana Moga, M. José
González Mingot, Cristina
Gallego, Yhovany
Quibus, Laura
Ramo Tello, Cristina
Presas Rodríguez, Silvia
Martínez Cáceres, Eva
Torres Cabestany, Pascual
Hervás, J.V.
Valls Marsal, Joan
Brieva Ruiz, Luis
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Multiple sclerosis
COVID-19
SARS-CoV-2
DMT
Seroprevalence
topic Multiple sclerosis
COVID-19
SARS-CoV-2
DMT
Seroprevalence
description Background: Disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) alter the immune system and therefore increase the risk of infection. There is growing concern about the impact of COVID-19 on patients with MS (pwMS), especially those treated with DMTs. Methods: This is a single-center prospective observational study based on data from the Esclerosis Múltiple y COVID-19 (EMCOVID-19) study. Demographic characteristics, MS history, laboratory data and SARS-CoV-2 serology, and symptoms of COVID-19 in pwMS treated with any DTM were extracted. The relationship among demographics, MS status, DMT, and COVID-19 was evaluated. Results: A total of 259 pwMS were included. The administration of interferon was significantly associated with the presence of SARS-CoV-2 antibodies (26.4% vs. 10.7%, p = 0.006). Although patients taking interferon were significantly older (49.1 vs. 43.5, p = 0.003), the association of interferon with the presence of SARS-CoV-2 antibodies was still significant in the multivariate analysis (OR 2.99 (1.38; 6.36), p = 0.006). Conclusions: According to our data, pwMS present a higher risk of COVID-19 infection compared with results obtained from the general population. There is no evidence of a worse COVID-19 outcome in pwMS. DMTs did not significantly change the frequency of COVID-19, except for interferon; however, these findings must be interpreted with caution given the small sample of pwMS taking each DMT.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.3390/jcm11092509
http://hdl.handle.net/10459.1/84518
url https://doi.org/10.3390/jcm11092509
http://hdl.handle.net/10459.1/84518
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a https://doi.org/10.3390/jcm11092509
Journal of Clinical Medicine, 2022, vol. 11, núm. 9, art. 2509.
dc.rights.none.fl_str_mv cc-by (c) Agustín Sancho Saldaña et al., 2022
info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
rights_invalid_str_mv cc-by (c) Agustín Sancho Saldaña et al., 2022
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405681953538048
score 15.811543

Similares en LA Referencia